AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26222559
Drug: ISIS 304801
RxNorm normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISIS 304801 (300 mg, add-on to fibrates)
Trial: 26222559
Drug: ISIS 304801
RxNorm normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISIS 304801 (all doses)
Trial: 23821878
Drug: Simultaneous technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous technique (two injections at the same time)
Trial: 23821878
Drug: Sequential technique
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential technique (one injection after the other)
Trial: 21875546
Drug: BUD/FM pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUD/FM pMDI 160/4.5 μg × 2 inhalations (320/9 μg) twice daily
Trial: 21875546
Drug: BUD pMDI
RxNorm normalized name: Clove buds
DrugBank: Clove (DB10672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUD pMDI 160 μg × 2 inhalations (320 μg) twice daily
Trial: 18001802
Drug: Toremifene 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toremifene 80 mg per day
Trial: 11097536
Drug: Neostigmine (0.005,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (0.005, 0.01, 0.02, or 0.05 mg x kg(‐1))
Trial: 11097536
Drug: Edrophonium (0.1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium (0.1, 0.2, 0.4, or 1 mg x kg(‐1))
Trial: 3718908
Drug: Topical haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical haloperidol
Trial: 29792287
Drug: GLPG1690 (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG1690 (600 mg oral once daily for 12 weeks)
Trial: 24519563
Drug: Aminophylline (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (75 mg intravenous, administered 90 seconds after (99m)Tc‐tetrofosmin injection)
Trial: 18927301
Drug: Immunohistochemistry test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunohistochemistry test using five monoclonal antibodies
Trial: 10815320
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (FEC-G) in addition to amikacin-ceftriaxone and other antibiotics
Trial: 10815320
Drug: Standard antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antibiotic therapy without granulocyte colony-stimulating factor
Trial: 1472833
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg per day
Trial: 1472833
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg per day
Trial: 1472833
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg per day + Gemfibrozil 450 mg per day
Trial: 6424087
Drug: Intravenous nitrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nitrogen intake (290 to 579 mg/kg/d)
Trial: 6424087
Drug: Nitrogen intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrogen intake (280 mg/kg/d)
Trial: 6424087
Drug: Recommended intravenous
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended intravenous amino acid intakes (2.3 to 2.7 g/kg/d)
Trial: 26850265
Drug: Subjects on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects on Tamoxifen or no endocrine therapy
Trial: 26850265
Drug: Subjects on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects on aromatase inhibitors (AIs)
Trial: 26850265
Drug: Subjects with
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with serum Vitamin D levels 20-29 ng/mL
Trial: 18827210
Drug: 4-IM (intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-IM (intramuscular administration of AVA at 0, 2, and 4 weeks and 6 months; n = 165-170)
Trial: 18827210
Drug: 3-IM (reduced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-IM (reduced 3-dose schedule of AVA; n = 501)
Trial: 18827210
Drug: 4-SQ (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-SQ (subcutaneous administration of AVA at 0, 2, and 4 weeks and 6 months; n = 165-170)
Trial: 18827210
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (saline injections at the same time intervals; n = 169)
Trial: 18827210
Drug: Route of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Route of administration
Trial: 10464886
Drug: Budesonide Turbuhaler
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide Turbuhaler 400 micrograms once daily in the evening
Trial: 10464886
Drug: Budesonide Turbuhaler
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide Turbuhaler 200 micrograms twice daily
Trial: 10464886
Drug: Budesonide Turbuhaler
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide Turbuhaler 200 micrograms once daily during the first open treatment period
Trial: 10464886
Drug: Budesonide Turbuhaler
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide Turbuhaler 100 micrograms once daily during the second open treatment period
Trial: 2169371
Drug: Sodium fluoride
RxNorm normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium fluoride (60 mg daily)
Trial: 27770279
Drug: Bevacizumab +
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab + Temozolomide (TMZ) 75-100 mg/m2 day 1-21 of 28 day cycle
Trial: 27770279
Drug: Bevacizumab +
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab + Irinotecan (CPT) 125 mg/m2 every 2 weeks
Trial: 9670867
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone and exercise intervention
Trial: 31174846
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg scopolamine
Trial: 3126956
Drug: beta blockers
RxNorm normalized name: BETA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta blockers (prior treatment)
Trial: 31256036
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral insulin (7.5 mg for 2 months, 22.5 mg for 2 months, 67.5 mg until age 36.0 months)
Trial: 31256036
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral insulin
Trial: 28291622
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (ezetimibe 10mg/d and rosuvastatin 10mg/d)
Trial: 28291622
Drug: High-dose rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose rosuvastatin (rosuvastatin 20mg/d)
Trial: 23267856
Drug: GSK249320 (0.04,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK249320 (0.04, 0.4, 1.2, 3.5, 10, and 25 mg/kg)
Trial: 19930866
Drug: Ramipril (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (up to 10 mg/day)
Trial: 19930866
Drug: Losartan (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (up to 100 mg/day)
Trial: 15021285
Drug: Intraoperative blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative blood loss in the hematoma group (762 ± 735 mL; median 500 mL)
Trial: 15021285
Drug: Intraoperative blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative blood loss in the control group (415 ± 403 mL; median 300 mL)
Trial: 11227030
Drug: 0.9 g
RxNorm normalized name: Mannose 0.9 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 g n-3 PUFA as fish oil
Trial: 11227030
Drug: 0.6 g
RxNorm normalized name: Ceo-Two, 0.9 g-0.6 g rectal suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 g n-3 PUFA as fish oil
Trial: 11227030
Drug: 0.3 g
RxNorm normalized name: sorbitol 0.3 GM Oral Lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 g n-3 PUFA as fish oil
Trial: 3148139
Drug: Concurrent articulation
RxNorm normalized name: follicle stimulating hormone / luteinizing hormone Injection [Menopur]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent articulation
Trial: 31862185
Drug: Neoadjuvant androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant androgen deprivation therapy (ADT)
Trial: 25500337
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg algal DHA supplementation (3 capsules per day)
Trial: 25500337
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg algal DHA supplementation
Trial: 23069814
Drug: Mechlorethamine, 0.02%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechlorethamine, 0.02%, gel
Trial: 23069814
Drug: Mechlorethamine, 0.02%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechlorethamine, 0.02%, compounded ointment
Trial: 18218285
Drug: Fast-dissolving ibuprofen
RxNorm normalized name: melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fast-dissolving ibuprofen caplets
Trial: 18218285
Drug: Regular release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular release ibuprofen caplets
Trial: 11974477
Drug: Surgical intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical intervention (not specified dosage or duration)
Trial: 8077573
Drug: 90 mmol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mmol/L L‐glutamine added to standard WHO oral rehydration salts (WHO‐ORS)
Trial: 8077573
Drug: Standard WHO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard WHO oral rehydration salts (WHO‐ORS)
Trial: 2572120
Drug: Corticosteroid cream
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid cream (clobetasol propionate)
Trial: 2572120
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream (base of the steroid cream)
Trial: 796950
Drug: Ketoprofen (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen (administered rectally at a dosage of 200 mg daily)
Trial: 26650153
Drug: Endobronchial valve
RxNorm normalized name: VALVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endobronchial valve treatment (EBV group)
Trial: 21890003
Drug: Added external
RxNorm normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Added external dead space (DS) 200 mL
Trial: 21890003
Drug: Added external
RxNorm normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Added external dead space (DS) 400 mL
Trial: 11675905
Drug: Moxifloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (400 mg tablet daily for 5 days)
Trial: 15013037
Drug: Co-amoxiclav (625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-amoxiclav (625 mg tablet every 8 hours for 7 days)
Trial: 9237640
Drug: Lovastatin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (60 mg/day)
Trial: 8217032
Drug: lovastatin 20
RxNorm normalized name: lovastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lovastatin 20 mg every day
Trial: 31965873
Drug: Multicomponent intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multicomponent intervention (home pharmacist visit, illustrated medication instructions, follow-up phone call)
Trial: 25434315
Drug: Lamivudine and
RxNorm normalized name: lamivudine and abacavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine and Adefovir dipivoxil (CLA) combination
Trial: 25434315
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with HBV DNA levels detectable but <10(4) copies/mL
Trial: 25434315
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with HBV DNA levels >10(4) copies/mL
Trial: 22474997
Drug: Yougui Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yougui Capsules at 1.68 g tid for 12 weeks
Trial: 10606840
Drug: Midazolam (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.15 mg kg‐1)
Trial: 10606840
Drug: Alpha-hydroxy-midazolam (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-hydroxy-midazolam (0.15 mg kg‐1)
Trial: 9148226
Drug: Torasemide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torasemide (20 mg/die)
Trial: 9148226
Drug: Furosemide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (50 mg/die)
Trial: 2946224
Drug: Etodolac 300
RxNorm normalized name: etodolac 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etodolac 300 mg bid
Trial: 2946224
Drug: Etodolac 500
RxNorm normalized name: etodolac 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etodolac 500 mg bid
Trial: 2946224
Drug: Piroxicam 20
RxNorm normalized name: piroxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 20 mg qd
Trial: 18029292
Drug: Optimised pharmacotherapy
RxNorm normalized name: Optimised human arginase I
DrugBank: Pegzilarginase (DB14780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimised pharmacotherapy for CHF
Trial: 12009084
Drug: Leukocyte depletion
RxNorm normalized name: Allogeneic thymocyte-depleted thymus tissue-agdc
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukocyte depletion by filtration with full-dose aprotinin
Trial: 28495642
Drug: Lenalidomide therapy
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide therapy (initiated at 5 mg every other day, increased to 10 mg daily if tolerated)
Trial: 28495642
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (withdrawal of immunosuppression followed by donor lymphocyte infusion)
Trial: 25577762
Drug: Selective prediction-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective prediction-based treatment
Trial: 23643110
Drug: Adherence to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence to treatment pathways
Trial: 19415804
Drug: MAL 160
RxNorm normalized name: maleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAL 160 mg/g with 1 h incubation
Trial: 19415804
Drug: MAL 160
RxNorm normalized name: maleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAL 160 mg/g with 3 h incubation
Trial: 19415804
Drug: MAL 80
RxNorm normalized name: maleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAL 80 mg/g
Trial: 9506002
Drug: Venlafaxine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine (50 mg every 8 hours for 7 days)
Trial: 9506002
Drug: Ethanol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.5 g/kg on days 5 and 7)
Trial: 31659242
Drug: Cinnamon supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnamon supplementation (3g daily)
Trial: 31659242
Drug: Placebo (3g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3g daily)
Trial: 27932411
Drug: MOD-4023 (once-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOD-4023 (once-weekly dosing at 18.5%, 37%, 55.5%, or 123.4% of individual cumulative weekly molar hGH dose)
Trial: 27932411
Drug: MOD-4023 (once-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOD-4023 (once-weekly dosing at 61.7% molar hGH content during Stage B)
Trial: 27932411
Drug: MOD-4023 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOD-4023 (various dosing cohorts)
Trial: 23441963
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg extract Sceletium tortuosum (Zembrin)
Trial: 23441963
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg extract Sceletium tortuosum (Zembrin)
Trial: 19416039
Drug: Modafinil (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (100 mg/d during weeks 1-2, 200 mg during weeks 3-4)
Trial: 7800355
Drug: Treatment groups
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment groups (specific treatments not detailed in the abstract)
Trial: 3279747
Drug: Sucrose (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose (120 g)
Trial: 3279747
Drug: Starch (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starch (120 g)
Trial: 11391261
Drug: Amoxicillin‐clavulanate potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin‐clavulanate potassium (2-week course)
Trial: 9404747
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ipratropium bromide (IB) and albuterol sulfate (ALB)
Trial: 9404747
Drug: Albuterol sulfate
RxNorm normalized name: Albuterol Sulfate
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol sulfate (ALB)
Trial: 3055923
Drug: Lovastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (20 mg twice daily)
Trial: 27090436
Drug: Statin prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin prescription
Trial: 12810502
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of alefacept
Trial: 12810502
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of alefacept
Trial: 10021470
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone treatment (0.3 mg per kilogram of body weight per week) for 2 to 10 years
Trial: 8672321
Drug: IL-1 receptor
RxNorm normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-1 receptor antagonist (IL-1ra) and TNF soluble receptors (TNFsr)
Trial: 8672321
Drug: Granulocyte adhesion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte adhesion molecule expression
Trial: 8672321
Drug: Fentanyl 175
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 175 micrograms with heparin 1050 u
Trial: 8672321
Drug: Heparin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin alone 1050 u
Trial: 1981223
Drug: Dipyridamole (DP)
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dipyridamole (DP) 50 mg 3 times a day
Trial: 1981223
Drug: ASA 300
RxNorm normalized name: ASA 300 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASA 300 mg once a day
Trial: 1981223
Drug: ASA 300
RxNorm normalized name: ASA 300 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASA 300 mg once in combination with DP 50 mg 3 times a day
Trial: 1981223
Drug: ASA 100
RxNorm normalized name: ASA 100 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASA 100 mg once a day
Trial: 1981223
Drug: ASA3 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASA3 group (combined ASA 300 mg and ASADP groups)
Trial: 27787547
Drug: Girentuximab (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Girentuximab (50 mg loading dose followed by 20 mg weekly for 24 weeks)
Trial: 25556383
Drug: N-acetylcysteine (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (1200 mg/day)
Trial: 21439642
Drug: povidone iodine
RxNorm normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: povidone iodine 2.5% solution
Trial: 21439642
Drug: tetracycline 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tetracycline 1% ointment
Trial: 18201138
Drug: Brimonidine tartrate
RxNorm normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brimonidine tartrate 0.2% twice-daily
Trial: 12898792
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate (Andriol) 160 mg/day for 3 months
Trial: 10534261
Drug: Vigabatrin (VGB)
DrugBank: Vigabatrin (DB01080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vigabatrin (VGB) at a target dose of 50 mg/kg
Trial: 1746428
Drug: Enalapril (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (2.5 mg orally at baseline and again 12 hours later)
Trial: 15220229
Drug: Antimicrobial therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial therapy for UTI